Omeros gains after OMS302 meets Phase III endpoint

Omeros Corp. (NASDAQ:OMER) gained $2.58 (34%) to $10.22 on Tuesday after OMS302 met the primary endpoint in a Phase III trial to maintain pupil dilation during cataract and other lens replacement surgery. Added to standard irrigation solution used during ophthalmological procedures, OMS302 led to superior maintenance of intraoperative pupil dilation vs. placebo (p<0.00001). ...